Tumor Necrosis Factor Inhibitor Drugs Market to hit USD 50 billion by 2032, says Global Market Insights Inc.
02 oct. 2024 05h42 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Tumor Necrosis Factor Inhibitor Drugs Market size valued at USD 41.3 billion in 2023 and is projected to grow at a CAGR of 2.2% from...
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
27 sept. 2024 09h00 HE
|
Alumis Inc.
Late breaking research presentation at EADV shows increasing and sustained responses in 28-week Phase 2 data for ESK-001 in psoriasis
U.S. Psoriasis Treatment Awareness & Satisfaction Report: A Review of 2023 - Provides Valuable Insights Into Must-Have Patient-Reported Data Points
26 sept. 2024 04h17 HE
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Psoriasis in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added to ...
Mindera Health™ becomes a Medi-Cal™ Credentialled Provider
19 août 2024 08h00 HE
|
Mindera Health
San Diego, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has completed the credentialling process to become a...
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
13 août 2024 16h05 HE
|
Alumis Inc.
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO...
Mindera Health Announces Appointment of Kamal Adawi as Chief Financial Officer
12 août 2024 08h00 HE
|
Mindera Health
San Diego, CA, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Ron Rocca, President and CEO of Mindera Health, said, “We’re very pleased to add Kamal to the executive team. I am thrilled to work with Kamal again...
[Latest] Global Medical Aesthetics Market Size/Share Worth USD 36,168.8 Million by 2033 at a 8.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
06 août 2024 03h30 HE
|
Custom Market Insights
Austin, TX, USA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Medical Aesthetics Market Size, Trends and Insights By Product Type (Aesthetic...
Mindera Health Secures $14 Million to Advance Commercialization of First and Only Psoriasis Precision Medicine Test
31 juil. 2024 08h00 HE
|
Mindera Health
San Diego, CA, July 31, 2024 (GLOBE NEWSWIRE) -- Mindera Health Inc. announces the closing of a $14M convertible note financing, led by Mountain Group Partners and other existing investors in...
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
29 juil. 2024 08h00 HE
|
Alumis Inc.
Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program for ESK-001 for the treatment of psoriasis.
$6.97 Billion Photodynamic Therapy Market Outlook, 2024-2032, Featuring Detailed Analysis of Gladerma, Sun Pharmaceutical Industries, Biofrontera, Lumibird, Bausch Health Companies, and More
06 juin 2024 04h22 HE
|
Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Photodynamic Therapy Market Report by Product Types, Application, End-user, Countries and Company Analysis 2024-2032" report has been added to ...